Last reviewed · How we verify
Geref (sermorelin)
Geref (generic name: sermorelin) is a sermorelin drug developed by Emd Serono. It is currently FDA-approved (first approved 1990) for Diagnostic Test for Growth Hormone Secretion, Pituitary dwarfism.
Geref (sermorelin) is a small molecule drug that targets the growth hormone-releasing hormone receptor. Originally developed by a pharmaceutical company, it is currently owned by Emd Serono and was FDA approved in 1990 for diagnostic testing of growth hormone secretion and treatment of pituitary dwarfism. As an off-patent medication with no active Orange Book patents, Geref is not commercially available as a generic. Key safety considerations include its short half-life of 0.19 hours. Geref is used to stimulate growth hormone release in the body.
At a glance
| Generic name | sermorelin |
|---|---|
| Sponsor | Emd Serono |
| Drug class | sermorelin |
| Target | Growth hormone-releasing hormone receptor |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
| First approval | 1990 |
Approved indications
- Diagnostic Test for Growth Hormone Secretion
- Pituitary dwarfism
Common side effects
Key clinical trials
- Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk (PHASE2)
- Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (PHASE2)
- Adult Growth Hormone Deficiency and Cardiovascular Risk (PHASE4)
- TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy (PHASE3)
- Tesamorelin Effects on Liver Fat and Histology in HIV (NA)
- The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment (PHASE1)
- The Effect of GHRH Therapy on Myocardial Structure and Function in Congestive Heart Failure (PHASE2)
- Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Geref CI brief — competitive landscape report
- Geref updates RSS · CI watch RSS
- Emd Serono portfolio CI
Frequently asked questions about Geref
What is Geref?
What is Geref used for?
Who makes Geref?
What is the generic name of Geref?
What drug class is Geref in?
When was Geref approved?
What development phase is Geref in?
What does Geref target?
Related
- Drug class: All sermorelin drugs
- Target: All drugs targeting Growth hormone-releasing hormone receptor
- Manufacturer: Emd Serono — full pipeline
- Therapeutic area: All drugs in Hematology
- Indication: Drugs for Diagnostic Test for Growth Hormone Secretion
- Indication: Drugs for Pituitary dwarfism
- Compare: Geref vs similar drugs
- Pricing: Geref cost, discount & access